Southwest Hospital, Army Medical University
陆军军医大学第一附属医院(西南医院)
Listed for 20 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Southwest Hospital, Army Medical University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌3 papers led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌0 papers led
- Hepatocellular carcinoma肝细胞癌57 papers led
- Stomach cancer胃癌23 papers led2 open trials led
- Osteosarcoma骨肉瘤7 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
- Neuroblastoma神经母细胞瘤0 papers led
- Multiple myeloma多发性骨髓瘤0 papers led
- Aplastic anaemia再生障碍性贫血2 papers led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
- Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征0 papers led
- Fanconi anaemia范可尼贫血1 paper led
- Moyamoya disease烟雾病2 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
- Duchenne muscular dystrophy杜氏肌营养不良0 papers led
- Behçet disease白塞病1 paper led
- IgA nephropathyIgA 肾病0 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎5 papers led
- Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
- Inherited epidermolysis bullosa遗传性大疱性表皮松解症0 papers led
Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Beta thalassaemia, Haemophilia A, Thrombotic thrombocytopenic purpura, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Chongqing for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma
No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led3
- Population-based nasopharyngeal carcinoma survival in southern China.
- Retrospective study of a novel hematological parameter for predicting the survival of patients with nasopharyngeal carcinoma.
- HILPDA-mediated lipidomic remodelling promotes radiotherapy resistance in nasopharyngeal carcinoma by accelerating mitophagy.
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led no English-language PubMed papers on oesophageal squamous cell carcinoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Chongqing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
More papers found outside PubMed (not counted)5
- Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Capsaicin inhibits migration and invasion via inhibiting epithelial-mesenchymal transition in esophageal squamous cell carcinoma by up-regulation of claudin-3 expression
Cancer
Hepatocellular carcinoma
肝细胞癌Led 57 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.
- Open trials led
- 0
- recruiting or about to
5 hospitals in Chongqing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingDigital Early Warning System for Acute Lung Injury in Liver Surgery
- Phase
- Not given
- Started
- 2024-11
- Registry
- NCT07070362
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Chongqing
- Not yet recruitingComparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
- Phase
- N/A
- Started
- 2025-06
- Registry
- NCT07010588
Age 18 years to 75 years (registered criteria)
Led by Peking University People's Hospital; 8 listed hospitals as study sitesBeijing, Changchun, Chongqing, Harbin, Jinan, Qingdao, Wuhan, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led57
- Noninvasive MRI imaging feature-based prediction of intratumoral tertiary lymphoid structure maturity in hepatocellular carcinoma: a multicenter retrospective study.
- Different approaches of laparoscopic anatomic hepatectomy of segment 7 for hepatocellular carcinoma: A multicenter study.
- Chronic stress impacts the prognosis of hepatocellular carcinoma patients after curative treatment by establishing a novel comprehensive classification: a cohort study and systematic review.
- Effect of Electric Fields on the Mechanical Mechanism of Regorafenib-VEGFR2 Interaction to Enhance Inhibition of Hepatocellular Carcinoma.
- Dynamic Profiles of Internal m7G Methylation on mRNAs in the Progression from HBV Infection to Hepatocellular Carcinoma.
- A novel hybrid model for predicting tertiary lymphoid structures and targeted immunotherapy outcomes in hepatocellular carcinoma: a multicenter retrospective study.
- Integrated ubiquitomics characterization of hepatocellular carcinomas.
- The immune-reinforcements of Lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment.
- Subsegmental radiofrequency ablation: a novel ablation technique based on portal territory for treatment of hepatocellular carcinoma.
- Indocyanine green fluorescence staining-guided laparoscopic posterosuperior segmentectomy: A multicenter retrospective cohort study.
- TGF-β induces a decrease in CAPZA1 expression to promote the invasiveness of hepatocellular carcinoma cells.
- Intersegmental veins between segments 5 and 8 as a landmark along the intersegmental planes during laparoscopic anatomical segmentectomy for hepatocellular carcinoma.
- The Taping Game for the Complex G8 Glissonean Approach Is the Most Effective Technique for Laparoscopic Anatomic S8 Resection of Dandelion-Patterned Hepatic Pedicles.
- Indocyanine Green Fluorescence-Guided Laparoscopic Anatomical Segmentectomy of Liver Segment 6: Surgical Strategy and Technical Details.
- The efficacy and safety of Radiofrequency ablation combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: a real-world study.
- Aptamer-bivalent-cholesterol-mediated proximity entropy-driven exosomal protein reporter for tumor diagnosis.
- Integrative multiomics analysis identifies molecular subtypes and potential targets of hepatocellular carcinoma.
- Upregulation of miR-3130-5p Enhances Hepatocellular Carcinoma Growth by Suppressing Ferredoxin 1 : miR-3130-5p Enhances HCC Growth via Inhibiting FDX1.
- Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma.
- Berberine increases the killing effect of pirarubicin on HCC cells by inhibiting ATG4B-autophagy pathway.
- Oxyberberine sensitizes liver cancer cells to sorafenib via inhibiting NOTCH1-USP7-c-Myc pathway.
- Anatomic Liver Resection Based on Portal Territory With Margin Priority for Hepatocellular Carcinoma.
- Evaluation and Prognostication of Gd-EOB-DTPA MRI and CT in Patients With Macrotrabecular-Massive Hepatocellular Carcinoma.
- LHX3 promotes EMT in hepatoma cell through β-catenin/TCF4 pathway.
- Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population.
- A Smart Nano-Theranostic Platform Based on Dual-microRNAs Guided Self-Feedback Tetrahedral Entropy-Driven DNA Circuit.
- FBXW10-S6K1 promotes ANXA2 polyubiquitination and KRAS activation to drive hepatocellular carcinoma development in males.
- Long-term efficacy of no-touch radiofrequency ablation in the treatment of single small hepatocellular carcinoma: A single center long-term follow-up study.
- Semaphorin 7A interacts with nuclear factor NF-kappa-B p105 via integrin β1 and mediates inflammation.
- Elevated FBXW10 drives hepatocellular carcinoma tumorigenesis via AR-VRK2 phosphorylation-dependent GAPDH ubiquitination in male transgenic mice.
- Elevated FBXL6 expression in hepatocytes activates VRK2-transketolase-ROS-mTOR-mediated immune evasion and liver cancer metastasis in mice.
- Elevated FBXL18 promotes RPS15A ubiquitination and SMAD3 activation to drive HCC.
- Effects of iodine-125 seed brachytherapy on patients with heterochronous pulmonary metastasis from hepatocellular carcinoma: A propensity score matching study.
- Open Radiofrequency Ablation Combined with Splenectomy and Pericardial Devascularization vs. Liver Transplantation for Hepatocellular Carcinoma Patients with Portal Hypertension and Hypersplenism: A Case-Matched Comparative Study.
- Degradation of helicase-like transcription factor (HLTF) by β-TrCP promotes hepatocarcinogenesis via activation of the p62/mTOR axis.
- Elevated FBXL6 activates both wild-type KRAS and mutant KRASG12D and drives HCC tumorigenesis via the ERK/mTOR/PRELID2/ROS axis in mice.
- In vivo analysis of FBXO45-mediated fibrosis and liver tumorigenesis in a chemically induced mouse model of hepatocellular carcinoma.
- Intermittent Pringle maneuver combined with controlled low Central venous pressure prolongs hepatic hilum occlusion time in patients with hepatocellular carcinoma complicated by post hepatitis B cirrhosis: a randomized controlled trial.
- The diagnostic value of contrast-enhanced ultrasound LI-RADS for hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis B.
- Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors Associated with Hepatocellular Carcinoma.
- Iodine-125 Seeds Inhibit Carcinogenesis of Hepatocellular Carcinoma Cells by Suppressing Epithelial-Mesenchymal Transition via TGF-β1/Smad Signaling.
- Radiofrequency ablation in the treatment of hepatocellular carcinoma.
- Risk factors for the recurrence of early hepatocellular carcinoma treated by percutaneous radiofrequency ablation with a multiple-electrode switching system: a multicenter prospective study.
- Laparoscopic Anatomical Versus Non-anatomical hepatectomy in the Treatment of Hepatocellular Carcinoma: A randomised controlled trial.
- The Short-Term Efficacy of Novel No-Touch Combined Directional Perfusion Radiofrequency Ablation in the Treatment of Small Hepatocellular Carcinoma with Cirrhosis.
- TACE with portal vein radioactive seeds for HCC with portal vein tumor thrombus: a meta-analysis.
- Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3/STAT3/BEX2 signaling.
- Laparoscopic liver resection for primary liver cancers originating in the paracaval portion of the caudate lobe: a preliminary retrospective analysis with 31 patients.
- ASO Author Reflections: A New Minimally Invasive Procedure for Hepatocellular Carcinoma with Situs Inversus Totalis.
- Pure Laparoscopic Anatomic Right Hemihepatectomy for Hepatocellular Carcinoma with Situs Inversus Totalis Using Indocyanine Green Fluorescence Staining (with Video).
- Rescue radiofrequency ablation or percutaneous ethanol injection: a strategy for failed RALPPS stage-1 in patients with cirrhosis-related hepatocellular carcinoma.
- FNDC4 acts as an extracellular factor to promote the invasiveness of hepatocellular carcinoma partly via the PI3K/Akt signalling pathway.
- Hepatopulmonary syndrome delays postoperative recovery and increases pulmonary complications after hepatectomy.
- T-lymphoma invasion and metastasis 1 promotes invadopodia formation and is regulated by the PI3K/Akt signaling pathway in hepatocellular carcinoma.
- p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma.
- Advanced hepatocellular carcinoma treated by radiofrequency ablation combined with oncolytic virus and anti-PD-1 antibody therapy: a case report and literature review.
- Elevated FBXO45 promotes liver tumorigenesis through enhancing IGF2BP1 ubiquitination and subsequent PLK1 upregulation.
Chinese-language papers (not in the count)2
- [Study of a nomogram model of gadoxetate disodium-enhanced magnetic resonance imaging for the preoperative diagnosis of proliferative hepatocellular carcinoma and its value].
- [Differentiation between hyperintense hepatocellular carcinoma and focal nodular hyperplasia in hepatobiliary phase with multimodal parameters of magnetic resonance imaging].
All its trials on ClinicalTrials.gov, any status28
- Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)
- A Study of Laparoscopic Middle Hepatic Vein Guidance and Traditional Anatomic Hemihepatectomy
- The Short-term Efficacy of Novel NTDP-RFA in the Treatment of Small HCC With Cirrhosis.
- Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma
- Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC
- No-touch RFA Versus Traditional RFA for Small Hepatocellular Carcinoma
- By Using Adoptive Transfer of Autologous NK Cells to Prevent Recurrence of Hepatocellular Carcinoma After Curative Therapy
- Radiofrequency Ablation Combined With Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma.
- A Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC
- Combined Treatment of RFA and Sorafenib on Recurrent HCC
- RALPPS Venus ALPPS for Hepatocellular Carcinoma
- Radiofrequency-assisted Hepatectomy on the Outcomes of HCC Patients With Cirrhosis
- Radiofrequency Ablation Assisted Hepatectomy Versus Hepatectomy Alone for Advanced Hepatocellular Carcinoma
- Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation (RFA) Associated With Postoperative TACE
- Effect of I/R Injuries by Pringle Manoeuvre on the Prognosis of HCC Patients After Curative Hepatectomy
- Laparoscopic Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy
- Recurrence Risk Factors of Early-Stage Hepatocellular Carcinoma After Radio Frequency Ablation
- Laparoscope Anatomical and Aon-anatomical Hepatectomy
- Laparoscopic Hepatectomy Versus Open Hepatectomy for PHC
- Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
- Digital Early Warning System for Acute Lung Injury in Liver Surgery
- A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
- Prospective Surveillance for Very Early Hepatocellular Carcinoma
- Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry
- the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma
- Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
- T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients
Cancer
Stomach cancer
胃癌Led 23 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.
6 hospitals in Chongqing for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingRobotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2025-02
- Registry
- NCT06791538
Age 18 years to 75 years (registered criteria)
Led by Southwest Hospital, Army Medical UniversityChongqing
- RecruitingA Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT06760858
Age 18 years to 80 years (registered criteria)
Led by Southwest Hospital, Army Medical UniversityChongqing
- RecruitingRadical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Phase
- Phase 3
- Started
- 2026-12
- Registry
- NCT07789184
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an
- RecruitingClinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
- Phase
- N/A
- Started
- 2024-09
- Registry
- NCT06128252
Age 18 years to 75 years (registered criteria)
Led by Tangdu Hospital; 11 listed hospitals as study sitesChongqing, Nanjing, Shanghai, Shenyang, Urumqi, Wuhan, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led23
- Clinicopathological features and diagnostic challenges of early gastric cardiac carcinoma with dysplastic gastritis cystica profunda: A case report.
- METTL1-WDR4 promotes the migration and proliferation of gastric cancer through N7-methylguanosine.
- Lopinavir enhances anoikis by remodeling autophagy in a circRNA-dependent manner.
- Association between textbook outcome and long-term survival among patients undergoing curative-intent resection of gastric cancer.
- Comparison of totally robotic and totally laparoscopic gastrectomy for gastric cancer: a propensity score matching analysis.
- Long-term oncological outcomes of robotic versus laparoscopic gastrectomy for gastric cancer: multicentre cohort study.
- Robotic Gastrectomy Versus Laparoscopic Gastrectomy for Gastric Cancer: A Multicenter Cohort Study of 5402 Patients in China.
- Long-term oncologic and surgical outcomes of robotic and laparoscopic gastrectomy for Siewert II/III esophagogastric junction carcinoma: A propensity score-matched retrospective cohort study.
- FasL+ PD-L2+ Identifies a Novel Immunosuppressive Neutrophil Population in Human Gastric Cancer That Promotes Disease Progression.
- PLXDC2 enhances invadopodium formation to promote invasion and metastasis of gastric cancer cells via interacting with PTP1B.
- A comparative study on perioperative outcomes between robotic versus laparoscopic D2 total gastrectomy.
- Surgical and survival outcomes after laparoscopic and open gastrectomy for serosa-invasive Siewert type II/III esophagogastric junction carcinoma: a propensity score matching analysis.
- Comparison of the Postoperative Complications Between Robotic Total and Distal Gastrectomies for Gastric Cancer Using Clavien-Dindo Classification: A Propensity Score-matched Retrospective Cohort Study of 726 Patients.
- Activated neutrophils polarize protumorigenic interleukin-17A-producing T helper subsets through TNF-α-B7-H2-dependent pathway in human gastric cancer.
- Expression, regulation and clinical significance of B7-H3 on neutrophils in human gastric cancer.
- Upregulation of Tubulointerstitial nephritis antigen like 1 promotes gastric cancer growth and metastasis by regulating multiple matrix metallopeptidase expression.
- Granulocyte-Macrophage Colony-Stimulating Factor-Activated Neutrophils Express B7-H4 That Correlates with Gastric Cancer Progression and Poor Patient Survival.
- Laparoscopic versus open gastrectomy for serosa-invasive gastric cancer: A single-center retrospective cohort study.
- Incidence and risk factors of postoperative complications after robotic gastrectomy for gastric cancer: an analysis of 817 cases based on 10-year experience in a large-scale center.
- Long-term oncologic outcomes of robotic versus laparoscopic gastrectomy for locally advanced gastric cancer: a propensity score-matched analysis of 1170 patients.
- Morbidity and short-term surgical outcomes of robotic versus laparoscopic distal gastrectomy for gastric cancer: a large cohort study.
- Learning curve of robotic distal and total gastrectomy.
- Gastric schwannoma treated by endoscopic full-thickness resection and endoscopic purse-string suture: A case report.
Chinese-language papers (not in the count)3
- [Preliminary Investigation of the Molecular Mechanism of Empagliflozin Suppressing Gastric Cancer Through Mammalian Target of Rapamycin].
- [Future prospect of robotic gastric cancer surgery].
- [Comparison of clinical efficacy and quality of life between uncut Roux-en-Y and Billroth II with Braun anastomosis in laparoscopic distal gastrectomy for gastric cancer].
All its trials on ClinicalTrials.gov, any status16
- Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer
- A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer
- Robotic and Laparoscopic Total Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer
- Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer
- A Clinical Research of CAR T Cells Targeting CEA Positive Cancer
- Long-term Oncologic Outcomes of Robotic Versus Laparoscopic Total Gastrectomy for Advanced Gastric Cancer
- Comparison of Vagus Nerve-preserving RADG and Conventional RADG for AGC
- A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
- Comparison of Laparoscopic Versus Open Gastrectomy for Advanced Gastric Cancer:A Prospective Randomized Trial
- Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
- Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
- Incidence of Pancreatic Fistula After Radical Gastrectomy
- Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer
- Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer
- Roux-en-Y vs. Roux-en-Y+ Pouch for D2 Total Gastrectomy
Cancer
Osteosarcoma
骨肉瘤Led 7 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
23 hospitals in Chongqing for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led7
- Inhibitors of APE1 redox and ATM synergistically sensitize osteosarcoma cells to ionizing radiation by inducing ferroptosis.
- Tantalum-Zirconium Co-Doped Metal-Organic Frameworks Sequentially Sensitize Radio-Radiodynamic-Immunotherapy for Metastatic Osteosarcoma.
- Retrospective review of safety and efficacy of anlotinib in advanced osteosarcoma with metastases after failure of standard multimodal therapy.
- Extracellular vesicles in tumorigenesis, metastasis, chemotherapy resistance and intercellular communication in osteosarcoma.
- An Exploration of Osteosarcoma Metastasis Diagnostic Markers Based on Tumor-Associated Neutrophils.
- Circular RNA circ-CHI3L1.2 modulates cisplatin resistance of osteosarcoma cells via the miR-340-5p/LPAATβ axis.
- Comparative efficacy of intraoperative extracorporeal irradiated and alcohol-inactivated autograft reimplantation for the management of osteosarcomas-a multicentre retrospective study.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)3
- Calponin 3 is associated with poor prognosis and regulates proliferation and metastasis in osteosarcoma.
- Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p.
- LncRNA LINC00628 overexpression inhibits the growth and invasion through regulating PI3K/Akt signaling pathway in osteosarcoma.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Chongqing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Cancer
Neuroblastoma
神经母细胞瘤Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Chongqing for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Blood disorders
Multiple myeloma
多发性骨髓瘤4 hospitals in Chongqing for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingClinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07569757
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
Blood disorders
Aplastic anaemia
再生障碍性贫血Led 2 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Chongqing for aplastic anaemia63 hospitals in China for aplastic anaemia
No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Chongqing for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
More papers found outside PubMed (not counted)1
Blood disorders
Atypical haemolytic uraemic syndrome
非典型溶血性尿毒症综合征Led no English-language PubMed papers on atypical haemolytic uraemic syndrome in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Chongqing for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome
No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Fanconi anaemia
范可尼贫血Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Chongqing for Fanconi anaemia40 hospitals in China for Fanconi anaemia
No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Moyamoya disease
烟雾病Led 2 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Chongqing for moyamoya disease47 hospitals in China for moyamoya disease
No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Chongqing for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)4
- Abnormal cortical-basal ganglia network in amyotrophic lateral sclerosis: A voxel-wise network efficiency analysis.
- Occipital cortical gyrification reductions associate with decreased functional connectivity in amyotrophic lateral sclerosis.
- Differential Impairment of Thalamocortical Structural Connectivity in Amyotrophic Lateral Sclerosis.
- Aberrant interhemispheric homotopic functional and structural connectivity in amyotrophic lateral sclerosis.
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Chongqing for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Other diseases
Behçet disease
白塞病Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Chongqing for Behçet disease149 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
IgA nephropathy
IgA 肾病Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
14 hospitals in Chongqing for IgA nephropathy346 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 5 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 1.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Chongqing for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis
No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led5
- Letter to the Editor: Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome-First report of the IAIHG retrospective registry.
- Extrahepatic Angiogenesis: A Potential Common Pathophysiological Basis of Multiple Organ Dysfunction in Rats with Cholestasis Cirrhosis.
- Melatonin attenuates cholestatic liver injury via inhibition of the inflammatory response.
- Unique DUOX2+ACE2+ small cholangiocytes are pathogenic targets for primary biliary cholangitis.
- Causal effect of autoimmune liver diseases on cancer: Meta-analyses of cohort studies and Mendelian randomization study.
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Chongqing for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis
No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Inherited epidermolysis bullosa
遗传性大疱性表皮松解症Led no English-language PubMed papers on inherited epidermolysis bullosa in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Chongqing for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa
No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Getting in touch
Name card to show staff or a driver
陆军军医大学第一附属医院(西南医院)
Southwest Hospital, Army Medical University
重庆
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Southwest Hospital; First Affiliated Hospital (Southwest Hospital); First Affiliated Hospital of Army Medical University; Southwest Hospital Affiliated to Third Military Medical University; Southwest Hospital of the Third Military Medical University; Southwest Hospital of Army Medical University; First Affiliated Hospital of the Army Medical University; First Affiliated Hospital, Third Military Medical University